Melanoma

Melanoma Treatment Trials

Protocol
Number

Title

ID

Novartis
MEK
162A2301
SLHN
2013-54

Two-arm, randomized, prospective, open-label, multi-center, phase III study to compare the efficacy and safety of MEK162 (45 mg BID) versus dacarbazine (1000 mg/m2 IV every 3 weeks) in patients with advanced (Stage IIIC) unresectable or metastatic (Stage IV) NRAS Q61 mutation-positive melanoma.

Learn more.

NCT01763164
Genentech
Roche
GO27826

This multi-center, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of vemurafenib in patients with completely resected, cutaneous BRAF-mutation positive melanoma at high risk for recurrence. Patients will be randomized to receive oral doses of vemurafenib 960 mg twice daily or matching placebo.

Learn more.

NCT01667419
BMS
CA184143

The purpose of this study is to examine the safety of Ipilimumab and patterns of use in the treatment of unresectable or metastatic melanoma in the post-approval setting.

Learn more.

NCT01511913
ZIOPHARM
AT 1001 101
SLHN
2012- 86

A Phase I/II, Open Label Study of Ad-RTS-hIL-12, an Adenovirus Vector Engineered to Express hIL-12, in Combination With an Oral Activator Ligand, in Subjects With Unresectable Stage III or IV Melanoma

Learn more.

NCT01397708
Prometheus
12PLK01

A Multi-Center Study of High Dose Aldesleukin (Interleukin-2) + Vemurafenib Therapy in Patients With BRAFV600 Mutation Positive Metastatic Melanoma

Learn more.

NCT01683188
ECOG
1609

A Phase III Randomized Study of Adjuvant Ipilimimab Anti-CTLA4 Therapy vs. High-Dose Interferon Alpha-2b for Resected High Risk Melanoma

Learn more.

NCT01274338

SLHN
2009-84
Provectus
PV10-
EA02

Open Label Expanded Access for Investigational Use of PV-10 in Patients who are not Eligible for an Existing PV-10 Clinical Trial for whom there is no Comparable or Satisfactory Approved Alternative Therapy & Whom in the Opinion of the Investigator may Benefit from PV-10 Administration NCT 0120779
Expanded Access
SLHN
2014-37
Expanded Access of MK-3475 in Metastatic Melanoma Patients With Limited to No Treatment Options

Learn more.
NCT02083484

COLUMBUS CMEK162B2301
2014-24

A Phase III Randomized, 3-arm, Open Label, Multicenter Study of LGX818 Plus MEK162 and LGX818 Monotherapy Compared With Vemurafenib in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma

Learn more.

NCT01909453